Histone deacetylases (HDACs) play a critical role in regulating gene expression through the balance of histone acetylation and deacetylation. Aberrant HDAC activity is linked to tumor development, as it affects key cellular processes such as cell proliferation, cell-cycle regulation, and apoptosis. HDACs are promising therapeutic targets for cancer treatment, and their inhibitors have been developed for clinical use. HDACs regulate gene expression through various mechanisms, including the formation of corepressor complexes, direct interaction with transcription factors, and deacetylation of both chromatin and non-histone proteins. In cancer, HDACs are involved in the repression of tumor suppressor genes and the promotion of tumor progression. Mutations in HDACs, such as HDAC2, can lead to resistance to HDAC inhibitors and contribute to cancer development. The loss of HDAC activity can lead to hyperacetylation of histones, which is associated with gene transcription deregulation. HDACs also regulate non-histone proteins, influencing cellular homeostasis. Sirtuins, a class of HDACs, are involved in various cellular processes, including gene expression, apoptosis, and DNA repair. Their dysregulation is implicated in cancer development. HDAC inhibitors, such as trichostatin A (TSA), have shown antitumor activity in various cancer cell lines and animal models. These inhibitors can induce gene expression changes, inhibit tumor growth, and enhance the sensitivity of cancer cells to chemotherapy and radiotherapy. The therapeutic implications of HDAC inhibitors are significant, as they can target multiple pathways involved in cancer progression. Clinical trials are ongoing to evaluate their efficacy in treating hematological and solid tumors. HDAC inhibitors, such as SAHA, have been approved for the treatment of certain cancers. Overall, HDACs are excellent targets for cancer treatment, and their inhibitors represent a promising approach in cancer therapy.Histone deacetylases (HDACs) play a critical role in regulating gene expression through the balance of histone acetylation and deacetylation. Aberrant HDAC activity is linked to tumor development, as it affects key cellular processes such as cell proliferation, cell-cycle regulation, and apoptosis. HDACs are promising therapeutic targets for cancer treatment, and their inhibitors have been developed for clinical use. HDACs regulate gene expression through various mechanisms, including the formation of corepressor complexes, direct interaction with transcription factors, and deacetylation of both chromatin and non-histone proteins. In cancer, HDACs are involved in the repression of tumor suppressor genes and the promotion of tumor progression. Mutations in HDACs, such as HDAC2, can lead to resistance to HDAC inhibitors and contribute to cancer development. The loss of HDAC activity can lead to hyperacetylation of histones, which is associated with gene transcription deregulation. HDACs also regulate non-histone proteins, influencing cellular homeostasis. Sirtuins, a class of HDACs, are involved in various cellular processes, including gene expression, apoptosis, and DNA repair. Their dysregulation is implicated in cancer development. HDAC inhibitors, such as trichostatin A (TSA), have shown antitumor activity in various cancer cell lines and animal models. These inhibitors can induce gene expression changes, inhibit tumor growth, and enhance the sensitivity of cancer cells to chemotherapy and radiotherapy. The therapeutic implications of HDAC inhibitors are significant, as they can target multiple pathways involved in cancer progression. Clinical trials are ongoing to evaluate their efficacy in treating hematological and solid tumors. HDAC inhibitors, such as SAHA, have been approved for the treatment of certain cancers. Overall, HDACs are excellent targets for cancer treatment, and their inhibitors represent a promising approach in cancer therapy.